Attenuated host resistance against Mycobacterium bovis BCG infection in mice lacking osteopontin

被引:137
作者
Nau, GJ
Liaw, L
Chupp, GL
Berman, JS
Hogan, BLM
Young, RA
机构
[1] MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA
[2] MIT, Dept Biol, Cambridge, MA 02142 USA
[3] Massachusetts Gen Hosp, Infect Dis Unit, Boston, MA 02114 USA
[4] Vanderbilt Univ, Med Ctr, Howard Hughes Med Inst, Nashville, TN 37232 USA
[5] Vanderbilt Univ, Med Ctr, Dept Cell Biol, Nashville, TN 37232 USA
[6] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02188 USA
[7] Vet Adm Med Ctr, Boston, MA 02130 USA
关键词
D O I
10.1128/IAI.67.8.4223-4230.1999
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Expression of the cytokine osteopontin (OPN) is elevated in granulomas caused by Mycobacterium tuberculosis. We tested the hypothesis that OPN contributes to host protection in a mouse model of mycobacterial infection. When infected with Mycobacterium bovis BCG, mice lacking a functional OPN gene had more severe infections characterized by heavier bacterial loads and a delayed clearance of the bacteria. The OPN-null mice had greater granuloma burdens consistent with the elevated bacterial load. The ability of osteopontin to facilitate the clearance of mycobacteria was most pronounced early after infection and appeared to be independent of known mediators of resistance to infection by mycobacteria: antigen-specific T-cell immunity, gamma interferon production, and nitric oxide production. BCG grew more rapidly in macrophages derived from OPN-null mice than in those from wild-type mice, demonstrating that the null phenotype was due to an intrinsic macrophage defect. These results indicate that osteopontin augments the host response against a mycobacterial infection and that it acts independently from other antimycobacterial resistance mechanisms.
引用
收藏
页码:4223 / 4230
页数:8
相关论文
共 51 条
  • [1] OSTEOPONTIN - ITS TRANSGLUTAMINASE-CATALYZED POSTTRANSLATIONAL MODIFICATIONS AND CROSS-LINKING TO FIBRONECTIN
    BENINATI, S
    SENGER, DR
    CORDELLAMIELE, E
    MUKHERJEE, AB
    CHACKALAPARAMPIL, I
    SHANMUGAM, V
    SINGH, K
    MUKHERJEE, BB
    [J]. JOURNAL OF BIOCHEMISTRY, 1994, 115 (04) : 675 - 682
  • [2] Boros D L, 1978, Prog Allergy, V24, P183, DOI 10.1159/000314417
  • [3] Carlson I, 1997, LAB INVEST, V77, P103
  • [4] EFFECTS OF NITRIC-OXIDE SYNTHASE INHIBITORS ON MURINE INFECTION WITH MYCOBACTERIUM-TUBERCULOSIS
    CHAN, J
    TANAKA, K
    CARROLL, D
    FLYNN, J
    BLOOM, BR
    [J]. INFECTION AND IMMUNITY, 1995, 63 (02) : 736 - 740
  • [5] KILLING OF VIRULENT MYCOBACTERIUM-TUBERCULOSIS BY REACTIVE NITROGEN INTERMEDIATES PRODUCED BY ACTIVATED MURINE MACROPHAGES
    CHAN, J
    XING, Y
    MAGLIOZZO, RS
    BLOOM, BR
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (04) : 1111 - 1122
  • [6] CHEN Y, 1992, J BIOL CHEM, V267, P24871
  • [7] Coligan J.E., 1994, CURRENT PROTOCOLS IM, V2
  • [8] Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol
    Condos, R
    Rom, WN
    Schluger, NW
    [J]. LANCET, 1997, 349 (9064) : 1513 - 1515
  • [9] DISSEMINATED TUBERCULOSIS IN INTERFERON-GAMMA GENE-DISRUPTED MICE
    COOPER, AM
    DALTON, DK
    STEWART, TA
    GRIFFIN, JP
    RUSSELL, DG
    ORME, IM
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (06) : 2243 - 2247
  • [10] THE PROTECTIVE IMMUNE-RESPONSE TO MYCOBACTERIUM-TUBERCULOSIS
    COOPER, AM
    FLYNN, JL
    [J]. CURRENT OPINION IN IMMUNOLOGY, 1995, 7 (04) : 512 - 516